THETFORD MINES, QC, Dec. 22, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce a collaboration with AstraZeneca Canada to support the utility of next-generation sequencing ("NGS") diagnostic testing for patients with metastatic breast cancer at Hôpital du Saint-Sacrement (CHU de Québec – Université Laval). NGS enables parallel analysis of multiple tumor genes to identify clinically actionable biomarkers and support faster, more informed treatment decisions.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
KDA GROUP ANNOUNCES A COLLABORATION TO INTEGRATE NEW CLINICAL ALERTS INTO THE MEDHERIZE PLATFORM TO SUPPORT THE ADOPTION OF NEXT-GENERATION SEQUENCING FOR BREAST CANCER PATIENTS
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
